Bisaramil hydrochloride | RGH-2957 | NK-1556 | CAS#96480-44-3 | 89194-77-4 | calcium channel antagonist

MedKoo Cat#: 328010 | Name: Bisaramil HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bisaramil, also known as NK-1556 and RGH-2957, is a calcium channel antagonist and sodium channel antagonist potentially for the treatment of arrhythmia.

Chemical Structure

Bisaramil HCl

CAS#96480-44-3 (HCl)

Theoretical Analysis

MedKoo Cat#: 328010

Name: Bisaramil HCl

CAS#: 96480-44-3 (HCl)

Chemical Formula: C17H24Cl2N2O2

Exact Mass: 0.0000

Molecular Weight: 359.29

Elemental Analysis: C, 56.83; H, 6.73; Cl, 19.73; N, 7.80; O, 8.91

Price and Availability

Size	Price	Availability
1mg	USD 350.00	Ready to ship
5mg	USD 950.00	Ready to Ship
10mg	USD 1,650.00	Ready to Ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

85927-98-6 (2HCl) 96480-44-3 (HCl) 89194-77-4 (free base)

Synonym

Bisaramil hydrochloride; Bisaramil HCl; NK-1556; NK 1556; NK1556; RGH-2957; RGH 2957; RGH2957; α-Yutac

IUPAC/Chemical Name

(1R,5S,9s)-3-ethyl-7-methyl-3,7-diazabicyclo[3.3.1]nonan-9-yl 4-chlorobenzoate hydrochloride

InChi Key

WLBQWCHCDDUUCW-UWHPFQGOSA-N

InChi Code

InChI=1S/C17H23ClN2O2.ClH/c1-3-20-10-13-8-19(2)9-14(11-20)16(13)22-17(21)12-4-6-15(18)7-5-12;/h4-7,13-14,16H,3,8-11H2,1-2H3;1H/t13-,14+,16-;

SMILES Code

O=C(O[C@@H]1[C@H]2CN(CC)C[C@@H]1CN(C)C2)C3=CC=C(Cl)C=C3.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# 89194-77-4 (Bisaramil free base) 96480-44-3 (Bisaramil hydrochloride)

Certificate of Analysis

View CoA: current batch, Lot#Y23X08M09

QC Data

View QC data: current batch, Lot#Y23X08M09

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 359.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Haruno A, Sugiyama A, Hashimoto K. Chronotropic, inotropic, dromotropic and coronary vasodilator effects of bisaramil, a new class I antiarrhythmic drug, assessed using canine isolated, blood-perfused heart preparations. Jpn J Pharmacol. 1999 Jul;80(3):267-70. PubMed PMID: 10461773. 2: Pugsley MK, Goldin AL. Effects of bisaramil, a novel class I antiarrhythmic agent, on heart, skeletal muscle and brain Na+ channels. Eur J Pharmacol. 1998 Jan 19;342(1):93-104. PubMed PMID: 9544797. 3: Paróczai M, Röth E, Kárpáti E. Bisaramil and antiarrhythmics as inhibitors of free radical generation. Pharmacol Res. 1997 Apr;35(4):279-85. PubMed PMID: 9264043. 4: Róth E, Lantos J, Temes G, Varga G, Paróczai M, Kárpáti E. Cardioprotection during heart ischemia-reperfusion. Acta Chir Hung. 1997;36(1-4):306-9. PubMed PMID: 9408384. 5: Lantos J, Röth E, Paróczai M, Kárpáti E. The effects of bisaramil and antiarrhythmics on free radical generation of isolated neutrophil granulocytes. Acta Chir Hung. 1997;36(1-4):186-7. PubMed PMID: 9408340. 6: Sunami A, Hiraoka M. Blockade of cardiac Na+ channels by a charged class I antiarrhythmic agent, bisaramil: possible interaction of the drug with a pre-open closed state. Eur J Pharmacol. 1996 Sep 26;312(2):245-55. PubMed PMID: 8894603. 7: Paróczai M, Roth E, Matos G, Temes G, Lantos J, Karpati E. Effects of bisaramil on coronary-occlusion-reperfusion injury and free-radical-induced reactions. Pharmacol Res. 1996 Jun;33(6):327-36. PubMed PMID: 8971954. 8: Pacher P, Kecskeméti V, Felkai R, Tószegi T, Matkovics B, Paróczai M. Effect of glutathione depletion on electrophysiological characteristics of guinea-pig ventricles. Acta Physiol Hung. 1996;84(3):319-21. PubMed PMID: 9219623. 9: Görög S, Bihari M, Csizér E, Dravetz F, Gazdag M, Herényi B. Estimation of impurity profiles of drugs and related materials. Part 14: the role of HPLC/diode-array UV spectroscopy in the identification of minor components (impurities, degradation products, metabolites) in various matrices. J Pharm Biomed Anal. 1995 Dec;14(1-2):85-92. PubMed PMID: 8833970. 10: Haruno A, Hashimoto K. Antiarrhythmic effects of bisaramil on triggered arrhythmias produced by intracoronary injection of digitalis and adrenaline in the dog. Jpn J Pharmacol. 1995 May;68(1):95-102. PubMed PMID: 7494388. 11: Pugsley MK, Saint DA. Tonic and use-dependent block of sodium currents in isolated cardiac myocytes by bisaramil. Br J Pharmacol. 1995 Jan;114(2):377-82. PubMed PMID: 7881737; PubMed Central PMCID: PMC1510250. 12: Yamawaki I, Bukovac SW, Sunami A. Synthesis and biological activity of the metabolites of syn-3-ethyl-7-methyl-3,7-diazabicyclo[3.3.1]non-9-yl 4-chlorobenzoate hydrochloride. Chem Pharm Bull (Tokyo). 1994 Nov;42(11):2365-9. PubMed PMID: 7859336. 13: Gémesi L, Kapás M, Matos L. Pharmacokinetic study of bisaramil in man. Acta Pharm Hung. 1993 Nov;63(6):327-33. PubMed PMID: 8116453. 14: Haruno A, Hashimoto K. Antiarrhythmic effects of bisaramil in canine models of ventricular arrhythmia. Eur J Pharmacol. 1993 Mar 16;233(1):1-6. PubMed PMID: 8472737. 15: Matsushima E, Sato T. Determination of bisaramil and its metabolite in plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1992 Jan 17;573(2):339-44. PubMed PMID: 1601972. 16: Paroczai M, Karpati E, Marko R, Kecskemeti V. Electrophysiological actions of a new antiarrhythmic drug, bisaramil, on isolated heart preparations. Pharmacol Res. 1992 Jan;25(1):75-85. PubMed PMID: 1738760. 17: Yamashita T, Sugimoto T. [Medical management of arrhythmias; newer antiarrhythmic drugs]. Nihon Rinsho. 1991 Nov;49(11):2680-6. Japanese. PubMed PMID: 1685198. 18: Sunami A, Sawanobori T, Adaniya H, Hiraoka M. Electrophysiological properties of a new antiarrhythmic agent, bisaramil on guinea-pig, rabbit and canine cardiac preparations. Naunyn Schmiedebergs Arch Pharmacol. 1991 Sep;344(3):323-30. PubMed PMID: 1961258. 19: Paroczai M, Karpati E. Investigations to characterize a new antiarrhythmic drug bisaramil. Pharmacol Res. 1991 Aug;24(2):149-62. PubMed PMID: 1684242. 20: Paróczai M, Kárpáti E, Solti F. The effects of bisaramil on experimental arrhythmias. Pharmacol Res. 1990 Jul-Aug;22(4):463-80. PubMed PMID: 2402479.